World Health Organization Sounds Concern Over Critical Scarcity of Obesity Medications

Under a tenth of individuals who could benefit from obesity jabs such as Wegovy have access to them, states the WHO as it issues its initial advice on the drugs.

Considering more than one billion individuals worldwide now living with obesity, it is calling for increased and just availability to these injectable treatments.

Per forecasts, more than two billion are projected to be living with obesity by 2030 without intervention.

"Our latest guidelines recognises that obesity is a long-term condition that can be treated with thorough and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and supply-chain constraints are key hurdles to widespread access to the treatments that can aid individuals in losing considerable body mass, notes the body.

GLP-1 Therapy Supply Crisis

Despite the current most favorable case, the production of such drugs could only cover around 100 million people – fewer than 10% of the global need, per the health organization.

The recommendation encourages countries and companies to increase availability, via measures such as licensing agreements.

Exclusive production rights on a key compound – the core component of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026.

The Way Obesity Drugs Operate

GLP-1 drugs replicate a biological compound to delay gastric emptying, suppress the appetite and increase feelings of fullness so people consume fewer calories.

Individuals commonly see weight reduction within a few weeks of starting on the once-weekly jabs.

Research suggests patients may put most of the weight back on within a year of discontinuing the drug, as their normal hunger come back.

To be overweight or obese raises your chance for experiencing medical conditions, such as diabetes, cardiovascular issues, stroke, and some malignancies.

Excess weight impacts individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the WHO.